Oncopeptides AB (LTS:0RN4)

kr 1.654 0 (0%) Market Cap: 349.01 Mil Enterprise Value: 216.16 Mil PE Ratio: 0 PB Ratio: 2.59 GF Score: 54/100

Q3 2024 Oncopeptides AB Earnings Call Transcript
Nov 07, 2024

kr1.6 (-23.70%)

Earnings
Q2 2024 Oncopeptides AB Earnings Call Transcript
Aug 14, 2024

kr2.38

Earnings
Q1 2024 Oncopeptides AB Earnings Call Transcript
May 30, 2024

kr2.82

Earnings
Q4 2023 Oncopeptides AB Earnings Call Transcript
Feb 27, 2024

kr4.99

Earnings
Q3 2023 Oncopeptides AB Earnings Call Transcript
Nov 08, 2023

kr5 (-5.97%)

Earnings
Q2 2023 Oncopeptides AB Earnings Call Transcript
Aug 10, 2023

kr5.87 (+1.82%)

Earnings
Q1 2023 Oncopeptides AB Earnings Call Transcript
May 04, 2023

kr6.35 (-21.68%)

Earnings
Q4 2022 Oncopeptides AB Earnings Call Transcript
Feb 16, 2023

kr7.22 (-4.11%)

Earnings
Q3 2022 Oncopeptides AB Earnings Call Transcript
Nov 09, 2022

kr10.18 (-10.42%)

Earnings
Oncopeptides AB special call Transcript
Sep 26, 2022
Q2 2022 Oncopeptides AB Earnings Call Transcript
Aug 11, 2022

kr33.77 (+8.96%)

Earnings
Oncopeptides AB to Discuss CHMP Positive Opinion Recommending Full Approval of Oncopeptides Pepaxti in EU Call Transcript
Jun 27, 2022
Q1 2022 Oncopeptides AB Earnings Call Transcript
May 04, 2022

kr5.88 (-4.35%)

Earnings
Q4 2021 Oncopeptides AB Earnings Call Transcript
Feb 17, 2022

kr6.56 (-1.31%)

Earnings
Oncopeptides AB Requesting Voluntary Withdrawal of the NDA of Pepaxto in the US Investor Call Transcript
Jan 24, 2022
Q3 2021 Oncopeptides AB Earnings Call Transcript
Nov 24, 2021

kr7.88 (-12.15%)

Earnings
Oncopeptides AB to Discuss Withdrawal of Pepaxto and Refocus on R&D - Conference Call Transcript
Oct 22, 2021
Oncopeptides AB to Present Data from OCEAN Study at International Myeloma Workshop (IMW) Transcript
Sep 12, 2021
Q2 2021 Oncopeptides AB Earnings Call Transcript
Aug 19, 2021

kr32.54 (+14.07%)

Earnings
Oncopeptides AB (publ) To Present Updated Ocean Results Call Transcript
Jul 08, 2021
Q1 2021 Oncopeptides AB Earnings Call Transcript
May 26, 2021

kr80.12 (-1.69%)

Earnings
Oncopeptides AB to Discuss Positive Topline Results From the Phase 3 OCEAN Call Transcript
May 25, 2021
Oncopeptides AB at Cowen Healthcare Conference (Virtual) Transcript
Mar 03, 2021
Oncopeptides AB (publ) - Special Call Transcript
Mar 01, 2021
Full Year 2020 Oncopeptides AB Earnings Call Transcript
Feb 18, 2021

kr116.26 (-1.26%)

Earnings

Q1 2024 Oncopeptides AB Earnings Call Transcript

May 30, 2024 / 07:00AM GMT

Release Date Price: kr2.82

Transcript

Sofia Heigis

Oncopeptides AB - Chief Executive Officer, Managing Director - Tyskland

Hi, everyone, and welcome to this presentation of our report for the first quarter of 2024. This is our standard disclaimer.

With me, I have Henrik Bergentoft who will give a financial update. Before that, I will go over some key points for the first quarter, additionally some events in the second quarter. This, given that we are reporting late in the spring due to our recent rights issue. I will then come back with an update of our European commercialization process and next step value drivers.

Starting off with some key highlights, we have already communicated the revenues for the first quarter, which arrived at SEK5.1 million. This is comparable to the revenue in Q4 of last year. The sales in the first quarter were influenced by seasonal effects, which we anticipated, as in line with the development for the full late-stage multiple myeloma market this season.

We have communicated that we expect an acceleration of sales in 2024 to reach profitability in 2026, which is still a valid guidance

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.